[CTIC] CTI BioPharma Corp.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.42 Change: 0.01 (2.35%)
Ext. hours: Change: 0 (0%)

chart CTIC

Refresh chart

Strongest Trends Summary For CTIC

CTIC is in the medium-term down -12% below S&P in 2 weeks. In the long-term down -84% below S&P in 2 years and down -99% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the tr

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 103.13% Sales Growth - Q/Q-84.66% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-147.4% ROE-518.67% ROI-316.19%
Current Ratio1.51 Quick Ratio1.41 Long Term Debt/Equity0.33 Debt Ratio1.97
Gross Margin98.47% Operating Margin-140.17% Net Profit Margin-151.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-3.04 M Cash From Investing Activities-20 K Cash From Operating Activities-24 M Gross Profit2.54 M
Net Profit-28.6 M Operating Profit-27.48 M Total Assets63.07 M Total Current Assets53.47 M
Total Current Liabilities35.38 M Total Debt15.24 M Total Liabilities45.39 M Total Revenue2.73 M
Technical Data
High 52 week2.19 Low 52 week0.64 Last close0.76 Last change0%
RSI16.67 Average true range0.04 Beta1.37 Volume496.44 K
Simple moving average 20 days-7.15% Simple moving average 50 days-0.13% Simple moving average 200 days-15.8%
Performance Data
Performance Week-1.3% Performance Month-12.64% Performance Quart-7.32% Performance Half-26.21%
Performance Year-60.82% Performance Year-to-date3.6% Volatility daily2.26% Volatility weekly5.05%
Volatility monthly10.36% Volatility yearly35.88% Relative Volume88.05% Average Volume132.31 K
New High New Low


2019-11-06 09:08:00 | CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

2019-11-04 16:05:00 | CTI BioPharma Reports Third Quarter 2019 Financial Results

2019-10-01 07:00:00 | CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

2019-08-01 16:05:00 | CTI BioPharma Reports Second Quarter 2019 Financial Results

2019-07-18 07:00:00 | CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration FDA Regarding Pacritinib for Treatment of Myelofibrosis

2019-06-13 07:00:00 | CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

2019-05-29 07:00:00 | CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

2019-05-02 18:40:41 | CTI BioPharma: 1Q Earnings Snapshot

2019-05-02 16:05:00 | CTI BioPharma Reports First Quarter 2019 Financial Results

2019-04-03 07:00:00 | CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10

2019-03-13 17:33:54 | CTI BioPharma: 4Q Earnings Snapshot

2019-03-13 16:05:00 | CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

2019-03-12 07:00:00 | CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19

2019-02-25 17:52:07 | CTI BioPharma ups CEO pay as stock hovers near record low

2019-02-20 07:00:00 | CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

2019-02-13 00:22:59 | CTI BioPharma collects $10M payment for former chemotherapy drug

2019-02-11 07:00:00 | CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

2019-02-08 18:25:37 | Ex-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissed

2019-02-01 07:01:00 | CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

2018-12-28 07:00:00 | CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

2018-12-18 16:01:00 | CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development

2018-12-17 19:53:47 | As CTI BioPharma restructures, former CEO James Bianco launches startup

2018-12-14 07:47:30 | The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

2018-12-13 14:20:42 | CTI BioPharma lays off half of workforce to save cash for lead drug trial

2018-12-13 10:03:00 | CTI BioPharma Announces Restructuring Plan

2018-11-26 16:01:00 | CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency

2018-11-23 07:35:00 | Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard — What Drives Growth in Today's Competitive Landscape

2018-11-01 12:10:04 | CTI BioPharma CTIC Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 09:40:32 | CTI BioPharma: 3Q Earnings Snapshot

2018-11-01 08:01:00 | CTI BioPharma Reports Third Quarter 2018 Financial Results

2018-10-25 07:01:00 | CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018

2018-10-01 10:05:02 | Is the Options Market Predicting a Spike in CTI BioPharma CTIC Stock?

2018-10-01 07:01:00 | CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

2018-09-26 07:01:00 | CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

2018-09-07 13:20:06 | CTI BioPharma co-founder comes to his own defense in yacht repossession lawsuit

2018-09-06 17:50:40 | CTI BioPharma co-founder and chief scientific officer leaves as stock sits near record low

2018-08-29 13:47:20 | Sheriff's deputies can't find CTI BioPharma founder to serve him lawsuit over repossessed yacht

2018-08-02 14:30:00 | CTI BioPharma Corp. to Host Earnings Call

2018-08-02 09:40:01 | CTI BioPharma CTIC Reports Q2 Loss, Tops Revenue Estimates

2018-08-02 08:36:16 | CTI BioPharma: 2Q Earnings Snapshot

2018-08-02 08:00:00 | CTI BioPharma Reports Second Quarter 2018 Financial Results

2018-07-26 16:01:00 | CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018

2018-07-19 11:14:03 | CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

2018-07-19 09:14:53 | Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

2018-07-19 08:00:00 | Today’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals

2018-07-18 15:25:30 | CTI BioPharma Has Fallen Almost 39% Today

2018-07-18 11:47:00 | Why CTI BioPharma Corp. Crashed Today

2018-07-18 07:00:00 | CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

2018-07-13 08:50:12 | Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

2018-07-10 09:33:01 | CTI BioPharma Falls After Failure of Pivotal Lymphoma Study